bound to an aminoglycoside. 7, 8 In the early 1960s, their chemical characterization experienced a substantial increase after anticancer therapeutic activity was described. They rank among the most effective and frequently used antineoplastic agents and remain indispensable components of modern chemotherapy protocols effective against a broad spectrum of solid tumours and leukaemia.
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| ANTIC AN CER MECHANIS M OF ANTHR AC YCLINE S
Fifty years on from its discovery, anthracycline antitumour and cardiotoxic mechanisms alike remain to evoke considerable interest in basic science research. 10 The exact mechanism of anthracycline-induced cardiotoxicity remains unclear; however, several pathways have been proposed (Figure 2 ).
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| Topoisomerase II poisoning
The principal molecular target for anthracyclines antitumour action is topoisomerase 2 (TOP2) in the proliferative cancer cells.
TOP2 is an adenosine triphosphate (ATP)-dependent enzyme, which is expressed as isoenzymes TOP2α and TOP2β in humans.
TOP2α is the most prevalent and is highly expressed in proliferating cells. Anthracyclines inhibit TOP2 upon formation of a ternary complex, consisting of double-stranded DNA, TOP2 and the anthracycline (DNA-TOP2-DOX). The stabilization of the cleavage complex impedes DNA resealing, resulting in double-stranded DNA breaks. When bound to TOP2α, the complex inhibits DNA replication and induces apoptosis as intended in proliferating malignant cells. 2, 5, 9, 10, 12, [14] [15] [16] [17] Damage to non-proliferating, quiescent cells, like the heart muscle, where TOP2β is the major form, results in heart muscle failure as a side effect. 17 
| Intercalation
After cellular uptake, DOX localizes primarily in the nucleus and binds to DNA by intercalation, inhibiting both ribonucleic acid (RNA) transcription and DNA replication. DOX prefers to insert its planar chromophore into intercalation site containing adjacent guanine-cytosine (GC) base pairs, probably due to specific hydrogen-bond formation between DOX and guanine. 11, 12, 18 Activation of DNA damage responses induces cell death independent of TOP2.
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| Oxidative stress
Doxorubicin-induced release of free radicals, due to its metabolism, may cause oxidative stress, resulting in DNA damage and cell death ( Figure 3) . 3, 12, 13 The quinone structure permits DOX to act as electron acceptors in reactions mediated by oxoreductive enzymes. Via one-electron reduction, most notably, cytochrome P450 reductase, the anthraquinone structure forms a semiquinone radical. 11, 13 Other enzymatic systems are also known to activate DOX as well, including xanthine oxidase and nitric oxide synthase. Semiquinone radicals may induce free-radical injury to DNA of themselves, particularly after interaction with molecular oxygen to generate superoxides, hydroxyl radicals and peroxides, causing DNA damage. The transfer of its unpaired electron will lead to the original quinone form.
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| ANTINEOPL A S TI C AG ENTS AND C ARDIOMYOPATHY
Success in treating cancer might be followed by defeat from lifethreatening conditions caused by cytotoxicity. 19 The most frequent type of cardiotoxicity in cancer treatment is anthracycline-related cardiomyopathy. 20 According to Lefrak et al, 21 repeated administration of anthracyclines can result in permanent cellular and interstitial damage,
The red-orange doxorubicin (DOX) and daunorubicin (DAU) have the planar ring system of the anthraquinone with resonating electronic structure in the A and C rings and conjugated quinone structure in the B ring. Paired phenolic groups on the C ring supply hydrogen bonding and a methoxy group at position 4 completes substituents on the rings A, B and C. The D ring is not part of the conjugated electron system, but its nonplanar characteristics are important for binding to macromolecules. At position 7, the D ring is linked to an aminoglycoside. Whereas the anthraquinone portion is quite water insoluble and lipophilic, the aminoglycoside is critical for water solubility of the molecules as well as their amphoteric properties. The only structural difference between DOX and DAU is the hydroxygroup on carbon 14 of the methyl ketone side chain. 
| DOXORUB ICIN -INDUCED C ARDIOTOXICIT Y
Although anthracyclines have been proven as useful antineoplastics, life-threatening cardiotoxicity as a side effect has been a limiting factor to their use. 9 It has long been considered that DOX exerts its anticancer and cardiotoxic action by distinct mechanisms: while the anticancer response was associated with DNA intercalation, TOP2 inhibition and apoptosis, the cardiotoxicity was mainly ascribed to oxidative stress. At present, it appears that such separation is not fully justified. It seems that beneficial (anticancer) and detrimental (cardiotoxic) responses to DOX are to some extent overlapping. 26, 27 Despite many years of research, the mechanisms have not been fully clarified.
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| Definition of cardiotoxicity
Cardiotoxicity is described by the National Cancer Institute in general terms as the "toxicity that affects the heart" (www.cancer.
gov/dictionary/). 28 However, historically, cardiotoxicity has been defined as a decrease in left ventricular ejection fraction (LVEF). 29 Unfortunately, there is not yet a consensus definition for cardiotoxicity that can be applied to all cancer types. 
| Incidence and risk factors
Anthracycline-related cardiotoxicity is broadly defined as acute onset (within the first week of therapy), early onset, and late onset (>1 year after therapy). Acute-onset toxicity, which occurs in <1% 
| Cardiotoxic mechanisms
Many pathways, as shown in Figure 4 and explained below, are involved in the anthracycline-induced cardiotoxicity. Each of them may play a role in causing cardiotoxicity via different mechanism, by themselves or in cooperation with other pathways. . C, DOX accumulates in the mitochondria due to the high affinity towards cardiolipin. D, The one-electron reduction of DOX to a semiquinone intermediate results in oxidative stress, leading to DNA damage, energy depletion and apoptosis. Furthermore, it impairs Ca 2+ processing in the sarcoplasmic reticulum and inhibits the transcription of important contractile elements. E, The two-electron reduction results in doxorubicinol production. Doxorubicinol, the primary circulating, highly toxic, metabolite from doxorubicin, shows a limited efflux. It is very potent at inhibiting the calcium pump of sarcoplasmic reticulum and other ion exchange pumps. ROS, reactive oxygen species; TOP2, topoisomerase 2 
| Molecular mechanisms
Oxidative stress
Doxorubicin-induced release of reactive oxygen species (ROS) causes oxidative stress, resulting in DNA damage and cell death.
Toxic metabolites
A two-electron reduction of the side chain carbonyl moiety converts anthracyclines to secondary alcohol, toxic metabolites at the myocardium level. The production of doxorubicinol in the case of DOX is up to 50 times more potent than the original compound at dysregulating Ca 2+ and iron homeostasis. 
| Histological pathophysiology
Repetitive induction of cardiomyocyte cell death without sufficient regenerative capacity is a plausible mechanism for DOX-induced cardiotoxicity. Indeed, when cumulative toxicity surpasses a threshold of repairable damage, a generic process of ventricular remodelling is triggered. 30 This remodelling includes alterations in cardiac gene expression leading to structural changes in the myocardial wall. 37 The main histological changes are shown in Table 1 .
| ErbB2/ERbB4 and NRG-1 signalling: cardiotoxicity of concomitant trastuzumab and anthracyclines
Anthracycline therapy renders cardiomyocytes more susceptible to alterations in Neuregulin-1 (NRG-1), a member of the epidermal growth factor (EGF) family, and protein-tyrosine kinase (ErbB) prosurvival pathway. 2, 38 Trastuzumab (TRZ), a monoclonal antibody against the ErbB2 that is found to be overexpressed in 25%-30% of breast cancer patients, is often used as adjuvant therapy in combination with DOX treatment. 39 , 40 Zeglinski et al proposed that the adjuvant use of TRZ could potentiate cardiomyocyte damage through a "dual-hit" mechanism, which includes inhibition of NRG-1 survival signalling pathway and Angiotensin II (ANGII)-induced activation of NADPH oxidase, increasing the ability to further ROS production as shown in Figure 5 . 19, 39 The potentiation of cardiac dysfunction of TRZ in conjunction with DOX could be due to the inherent ability of DOX to increase oxidative stress. 39 DOX administration produces a pool of vulnerable cardiomyocytes that are dependent on intact ErbB2-signalling for recovery, while TRZ blocks key receptors in the pathways that regulate cell survival.
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| S TR ATEG IE S FOR PRE VENTI ON
In Cardio-oncology, the best treatment for chemotherapy-induced cardiotoxicity is prevention. A detailed history focusing on cardiovascular risk factors, pre-existing cardiovascular disorders and previous exposure to chemotherapy agents is mandatory. A comprehensive assessment of the benefits from treatment vs potential risks of cardiotoxicity should be performed. 41 
| Primary prevention of cardiotoxicity from anthracyclines
Pharmacodynamic approaches can be applied for primary prevention of anthracycline-induced cardiotoxicity. Subsequently, the use of cardioprotective agents in conjunction with the treatment is a possibility. 16 Besides that, it is also important to know that some patients show a higher predisposition to develop HF and individual genotyping should be considered as a strategy for primary prevention in the future. 
| Continuous infusion
Early in the 1980s, administering DOX by continuous infusion over 48-96 hours evidenced to be an effective mean to reduce the development of clinically evident chronic heart failure (CHF), while not diminishing tumour objective action. 42 Recently, van Dalen et al 43 showed that an anthracycline infusion duration of 6 hours or longer diminish the occurrence of clinical HF and subclinical cardiac damage, while there was no significant difference in HF development using a peak dose of <60 mg/m² or 60 mg/m² or more. The advantage of replacing bolus administration with slow infusion is nonetheless counterbalanced by the patient's discomfort due to prolonged hospitalization and the exacerbation of exposure effects such as myelotoxicity, mucositis, and alopecia. 25, 33, 44 This strategy benefit is controversial in paediatric settings. 
| Liposomal doxorubicin
Replacing conventional anthracyclines with liposomal formulations, which alters pharmacokinetics and tissue distribution without affecting antitumour efficacy, can reduce cardiotoxicity. 46 Due to their size, liposomes are too big to cross the gap junctions of normal endothelium in the heart and many other healthy tissues, but diffuse more readily through the leaky vasculature of tumours. EPI is a semi-synthetic epimer of DOX, with an analogous oncological spectrum. Although the mechanism of action is similar to DOX, some of its physical, chemical and pharmacokinetic properties are different. 48 IDA, compared with DNR, has increased lipophilicity and cellular uptake and improved stabilization of a ternary drug-TOP2-DNA complex. 49 This drug may be administered orally, 50 and there is some controversy about whether IDA offers advantages over DOX or DNR regarding cardiac toxicity. 51 Also, the analogues amrubicin and the novel anthracenedione (pixantrone) are prominently less cardiotoxic, but they are used in limited conditions. 52,53
| Dexrazoxane
Given to the importance of oxidative stress, research has focused on drugs with antioxidant properties. 24, 25, 33 Exploratory clinical trials that probed the protective efficacy of high-dose vitamin E or N-acetylcysteine were uniformly disappointing. Dexrazoxane (DRZ), the only FDA-approved cardioprotective agent for anthracycline-induced cardiotoxicity, can chelate iron, before it converts O − 2 and H 2 O 2 into more potent OH˙. 54 It was previously thought to be the primary mechanism of cardioprotection; however, other antioxidants and iron-chelating agents have been tested in animal models and in humans, but the protective effect of some is uncertain. Thus, iron chelation and mitigation of oxidative stress might not represent the only prevailing mechanism of cardioprotection.
Indeed, DRZ precludes the formation of the ternary complex, DOX-DNA-TOP2ß, by forcing TOP2ß to assume a closed-clamp conformation ( Figure 6 ). Therefore, cardiomyocyte damage or death will be prevented. 9, 17, 33 In clinical trials, DRZ has reduced the incidence of CHF and augmented LVEF. 32 Unfortunately, controversy surrounds its use due to possible compromise of antineoplastic efficacy and increase in secondary tumours, myelosuppression and infection. 16, 24 Due to the latter concerns, its use in children was contraindicated cardiotoxicity was removed. 56 The field of oncology has accepted the potential benefits of DRZ. 57 Recently, Liesse et al generated predictions for treatment protocols with and without affiliated DRZ therapy. Noticeably, DRZ delayed the exponential rise in cardiotoxicity to doses of more than 400 mg/m², while without DRZ, the exponential rise in cardiotoxicity was observed with doses of more than 200 mg/m². 
| Pharmacogenetics/pharmacogenomics
The field of pharmacogenetics has been defined as the study of variability in drug response due to heredity. 59 More recently, the term "pharmacogenomics" has been introduced, which includes all genes in the genome that may determine drug response. 60 Different genetic factors are known to influence the balance between DOX efficacy and toxicity. Indeed, inherited differences in drug targets, metabolizing enzymes and transporters will influence pharmacokinetics and dynamics of drugs and will determine the drug effects. 61 Pharmacogenomics has been widely recognized as fundamental steps towards personalized medicine, which is of utmost importance for patients with high risk of developing cardiotoxicity from anthracyclines. 62 Leong et al indicated that several polymorphisms of pharmacogenetics candidates across the anthracyclines biochemistry and cardiomyopathy pathways are potentially a predictor for anthracycline-induced cardiotoxicity. However, the evidence is limited and further studies are needed to generate robust genetic predictor(s).
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F I G U R E 5 ErbB2/ErbB4 and NRG-1 signalling. A, Neuregulin (NRG-1) binds to ErbB4 with a high affinity, which dimerizes with ErbB2 in cardiomyocytes. This leads to signal transduction through the transmembrane helixes and activation of the intracellular kinase domain. B, Binding of trastuzumab to ErbB2 inhibits its dimerization with NRG-induced ErbB4 receptor. Binding of Angiontensin-2 to its receptor leads to NADPH oxidase activation and oxidative stress increase. Adjunct treatment with doxorubicin also increases oxidative stress. Such an increase in oxidative stress leads to apoptosis and consequently heart failure . NADPH, Nicotinamide Adenine Dinucleotide Phosphate Hydrogen; ROS, reactive oxygen species F I G U R E 6 DRZ can compete for the ADP-binding sites of TOP2β, inhibiting ATP hydrolysis and avoiding the formation of the ternary complex with doxorubicin (DOX). TOP2β is trapped in a closed-clamp form, preventing cell death. (A, anthracycline; ADP, adenosine diphosphate; DRZ, dexrazoxane; TOP2β, topoisomerase 2 β)
| Cardioprotective drugs for primary prevention-clinical update
Dexrazoxane is the only pharmacologic agent that is approved by the FDA to prevent cardiotoxicity in patients receiving anthracyclines. 54 However, to date, beta-blockers, renin-angiotensin inhibitors and statins have demonstrated promising results in studies evaluating their efficacy in primary prevention (Table 2) . 33 Indeed, both randomized and observational data demonstrate a potential cardioprotective role in patients receiving chemotherapy. [64] [65] [66] [67] [68] [69] [70] Two randomized trials recently tested whether primary prevention using these drugs during chemotherapy can reduce cardiotoxicity and preserve LVEF. 71, 72 Additionally, statins seem to have protective effects during chemotherapy based on a small randomized trial and TA B L E 2 Selected publications: primary prevention in patients without cardiac dysfunction observational studies. [73] [74] [75] However, there are significant limitations, including small sample size, low event rate, and short follow-up period. The modest effect on LVEF in the treatment groups must be analysed in the context of the relative lack of data concerning the natural history of asymptomatic LV dysfunction in cancer patients receiving cardiotoxic drugs. 33 
| CON CLUS ION
Anthracycline-induced cardiomyopathy is an important public health concern. To reduce the incidence, a deep understanding of its toxicity and mechanisms of action are crucial. There are some strategies to prevent the cardiac side effects; however, the only compound consistently found to be cardioprotective in experimental and clinical studies is the FDA-approved DRZ.
Larger randomized controlled trails in examining functional imaging techniques, biological parameters, and genetic alterations will be needed to ameliorate prediction, prevention and treatment of anthracycline-induced cardiotoxicity. In the emerging era of personalized cancer medicine, pharmacogenomics has been recognized as fundamental steps and may be effective to consign the cardiac effects of anthracycline to history. Anticancer druginduced cardiotoxicity should be viewed as a multidisciplinary approach including basic science, oncological and cardiological expertise, since advances in cancer treatment have greatly improved survival rates of children and adults with cancer. As this issue is still under large debate and no clear and defined
guidelines are yet available, oncologists and cardiologists must cooperate in the interest of best practice and the urgent need to prevent today's cancer patients from becoming tomorrow's cardiac patients.
